Literature DB >> 16477234

Immunosuppressive and trafficking properties of donor splenic and bone marrow dendritic cells.

Nikos Emmanouilidis1, Zhong Guo, Ying Dong, Marvin Newton-West, Andrew B Adams, Eun D Han Lee, Jun Wang, Thomas C Pearson, Christian P Larsen, Kenneth A Newell.   

Abstract

BACKGROUND: Infusion of donor dendritic cells (DC) has been shown to prolong allograft survival in a number of models. However, many regimens that utilize donor DC do not consistently produced tolerance or long-term allograft survival. We hypothesized that one factor limiting the therapeutic effect of donor DC is their relative inability to traffic to recipient peripheral lymph nodes and inhibit the function of resident alloreactive T cells.
METHODS: Donor strain DC isolated from the spleens or bone marrow of Flt3L-treated mice were transferred intravenously into recipients at the time of skin grafting. Where indicated, recipients were treated with an anti-CD40L antibody and CTLA4-Ig.
RESULTS: Infusion of donor DC together with costimulatory blockade promoted donor-specific prolongation of skin allograft survival in mice. Perhaps due to their more immature phenotype, bone marrow DC trafficked more effectively to the spleen, bone marrow, and thymus and were associated with significantly longer allograft survival than were splenic DC. Neither population of DC trafficked well to peripheral lymph nodes. Consistent with our hypothesis, splenic but not lymph node T cells from DC-treated recipients displayed donor-specific hyporesponsiveness in vitro.
CONCLUSION: These data suggest that one factor contributing to rejection following treatment with donor DC plus costimulation blockade is the persistence of donor-reactive T cells within the recipient's secondary lymphoid structures. Strategies to improve DC trafficking to these structures may enhance their therapeutic effect.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16477234     DOI: 10.1097/01.tp.0000195779.01491.4e

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  6 in total

1.  Secondary lymphoid tissue and costimulation-blockade resistant rejection: A nonhuman primate renal transplant study.

Authors:  Michael S Mulvihill; Kannan P Samy; Qimeng A Gao; Robin Schmitz; Robert P Davis; Brian Ezekian; Francis Leopardi; Mingqing Song; Tam How; Kyha Williams; Andrew Barbas; Bradley Collins; Allan D Kirk
Journal:  Am J Transplant       Date:  2019-04-12       Impact factor: 8.086

Review 2.  Back to the thymus: peripheral T cells come home.

Authors:  J Scott Hale; Pamela J Fink
Journal:  Immunol Cell Biol       Date:  2008-11-25       Impact factor: 5.126

3.  Divergent role of donor dendritic cells in rejection versus tolerance of allografts.

Authors:  Takuya Ueno; Katsunori Tanaka; Mollie Jurewicz; Takaya Murayama; Indira Guleria; Paolo Fiorina; Jesus C Paez; Andrea Augello; Andrea Vergani; Masie Wong; R Neal Smith; Reza Abdi
Journal:  J Am Soc Nephrol       Date:  2009-01-07       Impact factor: 10.121

4.  Flt3L combined with rapamycin promotes cardiac allograft tolerance by inducing regulatory dendritic cells and allograft autophagy in mice.

Authors:  Ali Xiong; Lihua Duan; Jie Chen; Zhigang Fan; Fang Zheng; Zheng Tan; Feili Gong; Min Fang
Journal:  PLoS One       Date:  2012-10-02       Impact factor: 3.240

Review 5.  Tolerogenic Dendritic Cells on Transplantation: Immunotherapy Based on Second Signal Blockage.

Authors:  Priscila de Matos Silva; Julia Bier; Lisiery Negrini Paiatto; Cassia Galdino Albuquerque; Caique Lopes Souza; Luis Gustavo Romani Fernandes; Wirla Maria da Silva Cunha Tamashiro; Patricia Ucelli Simioni
Journal:  J Immunol Res       Date:  2015-10-12       Impact factor: 4.818

Review 6.  Effects of Adoptive Transfer of Tolerogenic Dendritic Cells on Allograft Survival in Organ Transplantation Models: An Overview of Systematic Reviews.

Authors:  Yanni Zhou; Juan Shan; Yingjia Guo; Shengfu Li; Dan Long; Youping Li; Li Feng
Journal:  J Immunol Res       Date:  2016-07-28       Impact factor: 4.818

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.